1- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, KummerJA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol 189: 12-19.

2- Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.

3- Zur Hausen H . 2002. Papillomavirus and cancer: from basic studies to clinical applications. Nat Rev Cancer 2: 342 – 350.

4- Molina J, Guzmán Bistoni C, Méndez V, Blasco-Olaetxea E, García Tamayo J. 2005. Alteraciones cromosómicas en el cáncer del cuello uterino. En Vitae-Academia Biomédica Digital Octubre, diciembre 2005. http://vitae.ucv.ve/?module=articulo&rv=11&n=514.

5- Karsemaekers AM, van de Vijver MJ, Kenter GG, Fleuren GJ. 1999. Genetic alterations during the progresión of squamous cell carcinomas of the uterine cervix. Genes Chrom Cancer, 26:346-354.

6- García Tamayo J. 2006. Actualización sobre la historia del virus del papiloma humano en Venezuela y su relación con el cáncer cervical. En Vitae-Academia Biomédica Digital http://vitae.ucv.ve/?module=articulo&rv=7&n=228 Mayo-Agosto, 2006.

7- Busby-Earle RM, Steel CM, Williams AR, Cohen B, Bird CC. 1994, P53 mutations in cervical carcinogenesis-low frecuency and lack of correlation with human papilloma virus status. Br J Cancer 69: 732 –737.

8- Uchiyama M, Iwasaka T, Matsuo N, Hashisuga T, Moria M et al. 1997, Correlation between HPV and P53 gene overexpresion in adenocarcinoma of the uterine cervix. Gynecol Oncology 65:23-29.

9- Mittal KR, Lin O, Chan W, Goswami S, Demopoulus RI. 1995, Cervical squamous cell dysplasias and carcinomas with immunodetectable p53 frecuently contain HPV. Gynecol Oncol 58:289-294.

10- Alameda F, Baro T, Mariñosos ML, Manresa JM, Costa C, Espinet B, Fuste P, Mancebo G, Carreras R, Sole F, Serrano S. 2006, Carcinoma epidermoide invasor del cérvix uterino. Estudio de la expresion de p53, BCL-2, Ki 67, C-MYC y ciclina D1. Patología (Mex) 44: 87-96.

11- Ngan HY, TsaoSW, Stanley M. 1997, Abnormal expression and mutation of p53 in cervical cancer. A study at protein and DNA levels. Genitourin Med 73:54-58.

12- Horn L,C, Fisher U, Panel C, Kuhn H, Raptis G y col. 2001, P53 in surgically treated and pathologically satged cervical cancer: correlation with local tumor progression, but not with lymphatic spread. Pathol Res Pract 197, 605-609.

13- Oka K, Susuki Y, Nakano T. 2000, Expresión of p27 ans p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer 88: 2766-2773.

14- Hunt CR, Hale RJ, Buckley CH, Hunt J. 1996, P53 expression in carcinoma of the cervix. J Clin Pathol 49:971-974.

15- Cavuslu S, Goodland J, Hobbs C, Connor AM, Raju KS, et al. 1997, Relationship between human papillomavirus infectios and overxpresion of p53 protein in cervical carcinomas and lymph node metastases. J Med Virol 53: 111-117.

16- Grace VM, Shalini JV, Lekha TT, Devaraj SN, Devaraj H. 2003, Co-overexpresion of p53 and BCL 2 proteins in HPV induce squamous cell carcinomas of the uterine cervix. Gynecol Oncol 91: 51-58.

17- Tang SH, Cai QF, Ye XA. 2003, Expresion of bcl 2 and p53 protein in cervical epithelial carcinogenesis. Ai Zheng 22: 1057-1061.

18- Bitiren M, Cakmak EA, Gocmen A, Inaloz SS, Sari I, et al. 2003, The relationship between expression of p53/BCL2 and clinicopathologic criteria in cervix squamous cell carcinoma. Eur J Gynecol Oncol 24: 411-412.

19- Graflund M, Sorbe B, Karlson M. 2002, Immunohistochemical expression of p53, bcl-2 and p21 (WAF1/C1P1), in early cervical carcinoma: correlations with clinical outcome. Int, J Gynecol Cancer 12: 290-298.

20- Alameda FFP, Boluda S, Ferrer L, Baro T, Mariñoso L, et al. The Ki67 Labelling Index, is not a useful predictor for the follow up of cervical intraepithelial neoplasia1-. J Low Gen Tract Dis . 2004, 8: 313-316.

21- Donnellan R, Chetty R. 1999;Cyclin E in human cancers. FASEB J 13(8):773–80

22- Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. 2002,Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–75

23- Cho NH, Kim YT, Kim JW. 1997,Correlation between G1 cyclins and HPV in the uterine cervix. Int J Gynecol Pathol 16:339– 47

24- Quade BJ, Park JJ, Crum CP, Sun D, Dutta A. 1998, In vivo cyclin E expression as a marker for early cervical neoplasia. Mod Pathol 11:1238– 46

25- Tae KY, Kyoung CE, Hoon CN, Hung KJ, Ick YW, Wook KJ, et al. 2000, Expression of cyclin E and p27(KIP1) in cervical carcinoma. CancerLett 153:41– 50

26- Kanai M, Shiozawa T, Xin L, Nikaido T, Fujii S. 1998, Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix. Cancer 82:1709– 1719

27- Skomedal H, Kristensen GB, Lie AK, Holm R. 1999, Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 73:223–228.

28- Brychtova S, Brychta T, Sedlakova E, Kolar Z. 2004, Protoncogen C-Myc in uterine cervix carcinogenesis. Neoplasma 51: 84-89.

29- Uren A, Fallen S, Yuan H, Usubutun A, Kucukali T, et al. 2005, Activation of the casnonical WNT pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res 65: 6199-6206.

30- Sano T, Oyama T, Kashiwabara K Fukuda T, Nakajima T. 1998, Expression Status of p16 Protein Is Associated with Human Papillomavirus Oncogenic Potential in Cervical and Genital Lesions. Am J Pathol 153:1741–1748.

31- Agoff NF, Lin P, Morihara J, Mao C, Kiviat NB, Koutosky LA. 2003, P16INK4a expression correlates with degree of cervical neoplasia: a comparison with Ki67 expression and detection of High-risk HPV types. Mod Pathol 16: 665-673.

32- Keating JT, Cviko A, Reithdorf S, Reithdorf L, Quade BJ, Sun D, et al. 2001, Ki67, Cyclin E and p16INK4 are complementary surrogate biomarkers for human papillomavirus-related cervical neoplasia. Am J Surg Pathol 25: 884-891.

33- Midle-Langosch K, Riethdorf S, Kraus-Pöppinghaus A, et al. 2001, Expression of cyclin-dependent kinase inhibitors p16MTS1, 21WAF and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 439:55-61.

34- Van de Putte G, Holm R, Lie AK, y col. 2003, Expression of p27, p21 and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol 89:140-147

35- Van de Putte G, Kristensen GB, Lie AK, y col. 2004, Cyclins and proliferative markers in early squamous cervical carcinoma. Gynecol Oncol 94: 40-46.

36- Masoudi H, van Nieker DJ,Gilks CB, Cheang M, Bilek K, Fisher U, Ehlen T, Millera D, Horn LC. Loss of p16INK4 expression in invasive squamous cell carcinoma of the uterine cervix is an adverse prognostic marker. 2006, Histopathology 49: 542-545.

37- Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. 1997, Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11:2090–2100.

38- Sgambato A, Cittadini A, Faraglia B, Weinstein IB. 2000, Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 183:18–27

39- Zehbe I, Ratsch A, Alunni-Fabbroni M, Burzlaff A, Bakos E, Durst M, Wilander E, Tommasino M. 1999, Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions. Oncogene 18:2201–2211

40- Shiozawa T, Shiohara S, Kanai M, Konishi I, Fujii S, Nikaido T. 2001, Expression of the cell cycle regulator p27(Kip1) in normal squamous epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma of the uterine cervix: immunohistochemistry and functional aspects of p27(Kip1). Cancer 92:3005–3011

41- Skomedal H, Kristensen GB, Lie AK, Holm R. 1999, Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol, 73:223–228.

42- Tae KY, Kyoung CE, Hoon CN, Hung KJ, Ick YW, Wook KJ, Ho LS. 2000, Expression of cyclin E and p27(KIP1) in cervical carcinoma. Cancer Lett 153:41–50

43- Huang LW, Chao SL, Hwang JL, Chou YY. 2002, Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol Oncol 85:524–528

44- El Deiry WS, Harper JW, Hill DE, Jackman J, Mercer WE, O’Connor PM, Pietenpol JA, Velculescu VE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. 1994, WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169–1174

45- Giannoudis A, Herrington CS. 2000, Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 89:1300–1307

46- Sherr CJ, Roberts JM. 1995, Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149–1163.

47- Peifer M, Polakis P. 2000, Wnt signaling in oncogenesis and embryogenesis: a look outside the nucleus. Science 287:1606–1609.

48- Liu C, Li Y, Semenov M, et al. 2002, Control of h-cateninphosphorylation/ degradation by a dual-kinase mechanism. Cell 108:837–479.

49- Shtutman M, Zhurinsky J, Simcha I, et al. 1999, The cyclin D1 gene is a target of the h-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96:5522–5527.

50- Kikuchi A. 2000, Regulation of β-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 268: 243–248.

51- Üren A, Fallen S, Yuan H, Usubütün A, Kücükali T, Schlegel R, Toretsky JA. 2005, Activation of the Canonical Wnt Pathway during Genital Keratinocyte Transformation: A Model for Cervical Cancer Progression. Cancer Res 65: 6199-6206.

52-Brake T, Connor JP, Petereit DJ, Lambert PF. 2003. Comparative Analysis of Cervical Cancer in Women and in a Human Papillomavirus-Transgenic Mouse Model: Identification of Minichromosome Maintenance Protein 7 as an Informative Biomarker for Human Cervical Cancer. Cancer Research 63: 8173–8180.

53-Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M. Nevins JR. 2001.Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol. Cell. Biol., 21: 4684–4699.

54.-Cho NH, Kim YT, Kim JW. 1997.Correlation between G1 cyclins and HPV in the uterine cervix. Int. J. Gynecol. Pathol., 16: 339–347.

55-Kim YT, Choi EK, Cho NH, Ko JH, Yang WI, Kim JW, Lee SH. 2000. Expression of cyclin E and p27KIP1 in cervical carcinoma. Cancer Lett., 153: 41–50.

56-Freeman A, Morris LA, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N. 1999.Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin. Cancer Res., 5: 2121–2132.

57-Ohtani K, Iwanaga R, Nakamura M, Ikeda M, Yabuta N, Tsuruga H, Nojima H. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. 1999. Oncogene, 18: 2299–2309.

58-Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S,Crum, CP, Munger K. 2000. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. USA, 97: 10002–10007.

59- Cuadrado E, Rodriguez Trinidad A, Blasco-Olaetxea E, Torrado J, López Garcia JA, Arozena F. Blood Group Isoantigens ABO(H) in Transitional Carcinoma of the Bladder..Journal of Urology 1986, 135 :409-415

60- Torrado J, Blasco Olaetxea E, Cosme A, Gutierrez Hoyos A, Arenas JI, Cuadrado E. Immunohistologic reaction of 20 Monoclonal Antibodies against non A non B glycoconjugates with normal human gut. Blood. Transfusion and Inmunohemathology 1987, 5: 693-698

61- Blasco-Olaetxea E, Cuadrado E, Etxaniz P, Martinez de Salinas J, Cosme A, Torrado J. Immunological study of Blood Group substances in Recto colon diseases. J Clin Nutr Gastroenterology 1987, 2: 23-30

62- Torrado J, Gutierrez-Hoyos A, Blasco Olaetxea E, Larraz J. Immunohistological patterns of blood group ABO and type 1 chain (Lewis a Lewis b) and type 2 chain (H-2 Y) antigens in normal uterine cervix. Tissue Antigens 1990, 38: 8-11

63- Bara J, Mollicone R, Le Pendu J, Oriol R. Evidence of an antigen common to human intestine, endocervix and mucinous ovarian cysts present exclusively in Ale[b] patients. Bull Cancer 1985, 72: 104-107

64- Inoue M, Sasagawa T, Saito J. Expresión of blood group antigens ABH, Lewis a and Lewis b in fetal, normal and malignant tissues of the uterine endometrium. Cancer 1986, 60: 2985-2993

65- Sakamoto Y, Kamada M, Kishi Y, Mori T. A clinicopathologic implications of ABO (H) blood group substances in the primary lesion of the uterine cervical carcinoma. Acta Obstet Gynecol 1985, 37: 2090-2096

66- Alexander CW, Soong SJ, Shingleton HM, Gore H, Wilkerson JA, Hatch KD, Phillips D, Dollar JR. Immunohistochemistry of the blood group ABH isoantigens and Oxford Ca antigen as prognostic markers for stage IB squamous cell carcinoma of the cervix. Cancer 1986, 58: 2435-2096

67- Guzman C, Pinillos B, Blanco-Arias MC, Arenas A, Molina J, Garcia-Tamayo J, Blasco-Olaetxea E. Expression of blood group-related antigens in neoplastic uterine cervix. Aceptado para publicarse en Clinical & Translational Oncology, 2008.